The phototoxicity of phycocyanin subunit was enhanced by pegylated liposome against breast cancer

Journal of University of Science and Technology of China

Volumn 41, Issue 1, 2011, Pages 35-44

  Zhou, Tao ^a   Huang, Bei ^a   Zuo, Manman ^a   Guo, Ruiyong ^a   Wang, Yongzhong ^a   Niu, Jianfeng ^b  

^a ANHUI UNIVERSITY   (China)

^b INSTITUTE OF OCEANOLOGY   (China)

Author keywords

Breast cancer; Liposome; Photodynamic therapy; Phycocyanin subunit

Indexed keywords

EID: 84870571202     PISSN: 02532778     EISSN: None     Source Type: Journal    
DOI: 10.3969/j/issn.0253-2778.2011.01.006     Document Type: Article

References (25)

1. Medina O P, Zhu Y, Kairemo K. Targeted liposomal drug delivery in cancer [J]. Current Pharmaceutical Design, 2004, 10(24): 2 981-2 989.
2. Eriksen N T. Production of phycocyanin: A pigment with applications in biology, biotechnology, foods and medicine[J]. Applied Microbiology and Biotechnology, 2008, 80(1): 1-14.
3. Jiang Tao, Zhang Jiping, Chang Wenrui, et al. Crystal structure of R-phycocyanin and possible energy transfer pathways in the phycobilisome [J]. Biophysical Journal, 2001, 81(2): 1 171-1 179.
4. Patil G, Chethana S, Sridevi A S, et al. Method to obtain C-phycocyanin of high purity [J]. Journal of Chromatography A, 2006, 1127: 76-81.
5. Wang Zhijin,He Yuying,Huang Chaoguo,et al. Pharmacokinetics, tissue distribution and photodynamic therapy efficacy of liposomal-delivered hypocrellin A, a potential photosensitizer for tumor therapy[J]. Photochemistry and Photobiology, 1999, 70(5): 773-780.
6. Huang B.Antitumor studies of C-phycocyanin chromophore peptides mediated photodynamic therapy [J]. Acta Laser Biology Sinica, 2002, 11 (3): 194-198.
7. Tan Yang, Huang Bei, Ren Yanmin, et al. A study of pervasion character and PDT effect of phycocyanin subunits on cancer cell treatment [J]. Acta Laser Biology Sinica, 2007, 16(6): 684-688.
8. Love W G, Duk S, Biolo R, et al. Liposome-mediated delivery of photosensitizers: localization of zinc (H)-phthalocyanine within implanted tumors after intravenous administration [J]. Photochemistry and Photobiology, 1996, 63(5): 656-661.
9. Snyder JW,GrecoWR,BellnierDA, etal. Photodynamic therapy:A meanstoenhanceddrug delivery to tumors [J]. Cancer Research,2003,63 (23): 8 126-8 131.
10. Gabizon A, Goren D, Horowitz AT, et al. Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals[J]. Advanced Drug Delivery Reviews, 1997, 24: 337-344.
11. Klibanov A L, Maruyama K, Beckerleg A M, et al. Activity of amphipathic poly (ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target [J]. Biochimica et Biophysica Acta (BBA)-Biomembranes, 1991, 1062 (2): 142-148.
12. Sadzuka Y, Nakai S, Miyagishima A, et al. The effect of dose on the distribution of adriamycin encapsulated in polyethyleneglycol-coated liposomes [J]. Journal of Drug Targeting, 1995, 3(1): 31-37.
13. O'shaughnessy J A. Pegylated liposomal doxorubicin in the treatment of breast cancer [J]. Clinical Breast Cancer, 2003, 4(5): 318-328.
14. Perez AT, DomenechGH, FrankelC, etal. Pegylated liposomal doxorubicin (Doxil ®) for metastatic breast cancer: The Cancer Research Network, Inc., experience [J].Cancer Investigation, 2002, 20: 22-29.
15. Symon Z,Peyser A,Tzemach D,et al. Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes[J]. Cancer, 1999, 86(1): 72-78.
16. Johnston S R D,Gore M E. Caelyx®:PhaseI studies in ovarian cancer [J]. European Journal of Cancer, 2001, 37(Suppl 9): 8-14.
17. Fingar V H.Vascular effects of photodynamic therapy [J].Journal of Clinical Laser Medicine & Surgery, 1996, 14(5): 323-328.
18. Derycke A S L,de Witte P A M. Liposomes for photodynamic therapy [J]. Advanced Drug Delivery Reviews, 2004, 56(1): 17-30.
19. Torchilin V P.Targeted pharmaceutical nanocarriers for cancertherapyandimaging [J]. TheA APS Journal, 2007, 9(2): 128-147.
20. Abels C. Targeting of the vascular system of solid tumoursby photodynamic therapy (PDT)[J]. Photochemical &Photobiological Sciences,2004,3 (8): 765-771.
21. Maeda H. The enhanced permeability and retention (EPR)effect in tumor vasculature:the key role of tumor-selective macromoleculardrugtargeting [J]. Advances in Enzyme Regulation, 2001, 41: 189-207.
22. Maeda H,Wu J,Sawa T,et al. Tumor vascular permeability andthe EPR effectin macromolecular therapeutics:Areview [J]. JournalofControlled Release, 2000, 65: 271-284.
23. Igarashi A,Konno H, Tanaka T,et al.Liposomal photofrin enhances therapeutic efficacy of photodynamic therapy against the human gastric cancer [J]. Toxicology Letters, 2003, 145(2): 133-141.
24. SadzukaY,TokutomiK,IwasakiF,etal. The phototoxicity of photofrin was enhanced by PEGylated liposome in vitro[J].Cancer Letters, 2006, 241(1): 42-48.
25. PengQ, MoanJ, NeslandJ M Correlationof subcellular and intratumoral photosensitizer localization with ultrastructural features after photodynamic therapy[J].Ultrastructural Pathology, 1996, 20(2): 109-129.